Novartis is trading 6.98% up at $162.68 after remibrutinib met the primary endpoints in two Phase III relapsing multiple sclerosis trials, reducing relapse rates and inflammatory brain lesions versus teriflunomide.
- Novartis paused eight experimental rap-cel studies after three patient deaths linked to severe immune reactions.
- Investors appear focused on the oral MS treatment opportunity, while the safety disclosure tempers the rally.